Combination therapy of PD-1 axis binding antagonists and LRRK2 inhitibors

A method for increasing DC-mediated T cell priming in a subject, the method comprising administering a first effective amount of a selective LRRK2 inhibitor and a second effective amount of an anti-PD-L1 antibody, wherein the first effective amount of the selective LRRK2 inhibitor increases DC-mediated T cell priming in the subject, wherein the first effective amount of LRRK2 inhibitor is from about 10 mg/kg to about 300 mg/kg,

• wherein the selective LRRK2 inhibitor is selected from the group consisting of
• [4-[ ] 4-(ethylamino)-5-(trifluoromethyl) pyrimidin-2-yl] amino]-2-fluoro-5-methoxy-phenyl]-morpholino-methanone;
• 2-methyl-2-[3-methyl-4-[[4-(methylamino)-5-(trifluoromethyl) pyrimidin-2-yllamino] pyrazol-1-yl] propanenitrile;
• N2-[5-chloro-1-[3-fluoro-1-(oxetan-3-yl)-4-piperidyl] pyrazol-4-yl]-N4-methyl-5-(trifluoromethyl) pyrimidine-2,4-diamine;
• [4-[ ] 5-chloro-4-(methylamino) pyrimidin-2-yl] amino]-3-methoxy-phenyl]-morpholino-methanone;
• [4-[ ] 5-chloro-4-(methylamino)-3H-pyrrolo [2,3-d]pyrimidin-2-yl] amino]-3-methoxy-phenyl]-morpholino-methanone;
• 2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidine-1-carbonyl] anilino]-5,11-dimethyl-pyrimido [4,5-b][1,4] benzodiazepin-6-one;
• 3-(4-morpholino-7H-pyrrolo [2,3-d]pyrimidin-5-yl) benzonitrile;
• cis-2,6-dimethyl-4-[6-[5-(1-methylcyclopropoxy)-1H-indazol-3-yl] pyrimidin-4-yl] morpholine;
• and
• 1-methyl-4-(4-morpholino-7H-pyrrolo [2,3-d]pyrimidin-5-yl) pyrrole-2-carbonitrile;
• or a pharmaceutically acceptable salt thereof, and
• wherein the anti-PD-L1 antibody is atezolizumab.